New Zealand markets closed

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
5.07-0.04 (-0.78%)
At close: 04:00PM EDT
5.24 +0.17 (+3.35%)
After hours: 07:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 637.75M
Enterprise value 712.72M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.77
Price/book (mrq)N/A
Enterprise value/revenue 7.50
Enterprise value/EBITDA -3.31

Trading information

Stock price history

Beta (5Y monthly) 1.33
52-week change 3-51.81%
S&P500 52-week change 3-3.56%
52-week high 312.89
52-week low 32.19
50-day moving average 33.25
200-day moving average 36.21

Share statistics

Avg vol (3-month) 33.02M
Avg vol (10-day) 35M
Shares outstanding 5118.76M
Implied shares outstanding 6N/A
Float 877.35M
% held by insiders 10.24%
% held by institutions 1115.57%
Shares short (28 Jul 2022) 440.43M
Short ratio (28 Jul 2022) 416.79
Short % of float (28 Jul 2022) 452.26%
Short % of shares outstanding (28 Jul 2022) 439.45%
Shares short (prior month 29 Jun 2022) 436.44M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 312 Jan 2014

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin -239.34%
Operating margin (ttm)-229.19%

Management effectiveness

Return on assets (ttm)-41.97%
Return on equity (ttm)-328.53%

Income statement

Revenue (ttm)94.97M
Revenue per share (ttm)0.93
Quarterly revenue growth (yoy)23.10%
Gross profit (ttm)-90.5M
EBITDA -214.73M
Net income avi to common (ttm)-227.3M
Diluted EPS (ttm)-2.29
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)83.54M
Total cash per share (mrq)0.81
Total debt (mrq)158.51M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.77
Book value per share (mrq)-0.21

Cash flow statement

Operating cash flow (ttm)-170.74M
Levered free cash flow (ttm)-65.82M